

# Continuing Education Quiz

## Advances in Cancer Chemotherapy 2006: Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Nelarabine

- All of the following statements about Arranon are true EXCEPT:
  - it is approved for use in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  - it was cleared under FDA's accelerated approval program.
  - it received Orphan Drug designation.
  - its sponsor has 14 years of exclusive U.S. marketing.
- The correct term defining the formation and development of blood cells is:
  - hematocephalus.
  - hematopoiesis.
  - hematomyelitis.
  - hemostasis.
- The correct term defining immature lymphoid cells in acute lymphoid leukemia is:
  - blasts.
  - clasts.
  - chromocytes.
  - basophils.
- The primary differentiation between acute and chronic forms of leukemia is that with the chronic form, bone marrow cells:
  - do not reach maturity and immature cells accumulate.
  - appear mature, but are abnormal in function.
- The correct term defining clinically evident bleeding, in the form of small, pinpoint, nonraised blood spots on the skin's surface is:
  - angioedema.
  - hematomas.
  - ecchymoses.
  - petechiae.
- Lymph nodes containing lymphomatous cells generally are characterized by all of the following EXCEPT:
  - they are firm.
  - they are nontender.
  - they are infected.
- Nelarabine is a T-cell-selective cytotoxic prodrug of:
  - deoxyadenine.
  - deoxyguanosine.
  - deoxycytosine.
  - deoxythymidine.
- Which of the following is NOT included in the most common hematologic adverse events seen in children receiving Arranon?
  - Eosinopenia
  - Neutropenia
  - Leukopenia
  - Thrombocytopenia
- Patients receiving Arranon should be advised to tell their doctor right away if any of the following occur EXCEPT:
  - altered taste.
  - being more tired than usual.
  - trouble breathing.
- All of the following statements about Arranon are true in pediatric dosing EXCEPT:
  - the recommended dose is 650 mg/m<sup>2</sup>.
  - it is to be administered daily for five days.
  - the dosage regimen is to be repeated every 21 days.
  - it must be further diluted before it is administered.

# Advances in Cancer Chemotherapy 2006: Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Nelarabine

May 2006 ACPE # 129-047-06-002-H01

The Ohio Pharmacists Foundation Inc and NDSU College of Pharmacy are approved by ACPE as providers of continuing pharmaceutical education. To receive 1 1/2 hours (0.15 CEUs) of continuing education credit, complete the following and mail with \*\$10.00 to:

Continuing Education Secretary  
College of Pharmacy  
North Dakota State University  
Sudro Hall, Room 123  
Fargo, ND 58105

*\*Fee increase due to industry support cutbacks.*

Name \_\_\_\_\_

Social Security Number (SSN) \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_

Zip \_\_\_\_\_

Your SSN will be used to maintain a permanent record of the courses you have taken. Your SSN will be kept confidential and will be used ONLY to identify you at NDSU.

**Answer sheet may be copied as needed but original of answers is required.**

## COURSE EVALUATION

*Evaluation Must Be Completed To Obtain Credit*

How much time did this lesson require? \_\_\_\_\_

Today's Date \_\_\_\_\_

**EXPIRATION DATE: 2-15-09**

Learning objectives on first page were addressed.

**1 Disagree - 5 Agree**

Objective 1 1 2 3 4 5

Objective 2 1 2 3 4 5

Objective 3 1 2 3 4 5

Material was well organized and clear. 1 2 3 4 5

Content sufficiently covered the topic. 1 2 3 4 5

Material was non-commercial in nature. 1 2 3 4 5

### Answer Sheet:

1. a b c d 6. a b c

2. a b c d 7. a b c d

3. a b c d 8. a b c d

4. a b 9. a b c

5. a b c d 10. a b c d